*Read Disclaimer Sponsored Content
{{current_date_full}} | Unsubscribe
Hello!
New Alert: Klotho Neurosciences, Inc. (Nasdaq: KLTO)
KLTO is our brand new NASDAQ alert.
The company has a chart setup positioning for a potential breakout higher.
Moreover, it has a history of large moves in a short period of time.
In June, the company traded over 3.00…
That’s over 250% from here.
But it doesn’t have to go up that high to experience double- or triple-digit gains.
KLTO has a 50 day moving average of 1.18, 37% above Friday’s close.
Large gaps like this often create big opportunities.
Now might be no different.
The momentum may already be in place.
With a chart setup pointing to a breakout opportunity.
In addition, this morning the company announced breaking news.
KLTO is a NASDAQ listed “biogenetics” and “biotechnology company”.
KLTO is “focused on the development of innovative, disease-modifying cell and gene therapies”.
KLTO uses “a protein derived from a patented form of the "anti-aging" human Klotho gene (s-KL), and its novel delivery systems”.
KLTO objective is “to transform and improve the treatment of neurodegenerative and age-related disorders such as ALS, Alzheimer's disease, and Parkinson's disease”.
Amyotrophic Lateral Sclerosis (ALS), or Lou Gehrig's disease, is a “terminal neurodegenerative disorder that results in the progressive loss of both upper and lower motor neurons that normally control voluntary muscle contraction”.
Sadly, it’s a “Rare Disease with Limited Treatment Options”.
ALS “affects fewer than 200,000 people in the US, with around 5,000 new cases diagnosed each year”.
In July, the company announced:
“Klotho Neurosciences, Inc. Granted FDA Orphan Drug Designation for KLTO-202 for Treatment of Amyotrophic Lateral Sclerosis ("ALS" or "Lou Gehrig's Disease")”
Benefits of Orphan Drug Designation:
“7 Years of Market Exclusivity: No other company can market the same drug for the same indication during this period.”
“Tax Credits: Up to 25% of clinical trial costs can be claimed as tax credits.”
“Waiver of FDA Fees: Application fees for FDA review are waived, saving companies millions of dollars. Grants and Funding: Access to grants to support clinical trial costs.”
“Assistance in Drug Development: Companies receive FDA guidance on the clinical trials and approval process.”
As the company further explains:
“KLTO-202, the company's lead product candidate targeting motor neuron diseases and muscular dystrophies, is composed of a muscle-specific promoter called "desmin," driving the expression of the s-KL gene transcript and s-KL protein, with targeted delivery of the gene therapy to the neuromuscular junction - the interface between the spinal cord and the muscles. At this time, KLTO-202 is not approved for human use by any regulatory authority.”
Meanwhile, “Alzheimer’s Disease is a progressive, age-related neurodegenerative disease affecting memory, cognition, and behavior. It is the most common cause of dementia, accounting for 60-80% of cases.”
Sadly, “Over 6 million Americans are living with Alzheimer’s” with “Cost of Care for those patients is over $350 billion”.
In addition to its “core programs targeting brain aging and neurodegenerative diseases such as ALS, Alzheimer's, and Parkinson's, the Company is now seeking to expand into adjacent technologies that complement its proprietary anti-aging Klotho platform”.
Importantly:
“The goal is to slow biological aging and reduce the burden of age-related diseases—ultimately promoting a longer, healthier life.”
As the company further explains:
“The human Klotho gene is strongly linked to aging and longevity.”
“Klotho levels decline with age, contributing to age-related disorders such as cardiometabolic disease, neurodegeneration, cancer, sarcopenia (muscle wasting), osteoporosis, and general fatigue.”
“Silencing of the Klotho gene has been shown to accelerate multi-organ deterioration.”
The Company's “current portfolio consists of its proprietary cell and gene therapy programs using DNA and RNA as therapeutics and genomics-based diagnostic assays”.
KLTO is “managed by a team of individuals and advisors who are highly experienced in biopharmaceutical product development and commercialization”.
KLTO has announced multiple accomplishments recently.
In June, the company announced a big accomplishment:
“Klotho Neuroscience, Inc. Announces An Approach To Increase Longevity And Healthy Life Span - Replace A Silenced Gene Called Alpha-Klotho ("Α-Klotho")”
“Recent clinical and pre-clinical studies and analysis indicates the potential to increase lifespan and reduce age-associated degeneration in multiple organ systems has be realized with a focus on the human gene called Klotho.”
In addition, the company also announced multiple big developments:
“Klotho Neurosciences Raises Over $11 Million, Retires All Debt, And Exceeds Nasdaq Stockholders' Equity Requirement”
“Klotho Neurosciences, Inc. and the Okinawa Research Center for Longevity Science, Leading Experts on the Okinawa "Blue Zone", Announce a Plan to Study Tissue Levels of the Human Klotho Gene and Protein in the World's Longest-Lived Population”
“Klotho Neurosciences Moves Forward with Manufacturing Gene Therapy for the Treatment of ALS”
As we previous mentioned, in July, the company announced a big accomplishment:
“Klotho Neurosciences, Inc. Granted FDA Orphan Drug Designation for KLTO-202 for Treatment of Amyotrophic Lateral Sclerosis ("ALS" or "Lou Gehrig's Disease")”
Here are some of the company’s comments from this press release:
"Receiving the Orphan Drug Designation for s-KL-AAV.myo for the early treatment of ALS underscores the importance of bringing new treatment options to patients suffering from this rare, universally fatal disease" said Dr. Joseph Sinkule, Klotho's Chief Executive Officer. "My cousin Karen died from this horrific disease. We aim to deliver the first gene replacement therapy addressing the neurologic insult resulting in motor neuron damage and the potential neurologic protection induced by providing therapeutic blood, brain, and muscle concentrations of the s-KL protein. After the FDA's review of the data leading to the Orphan Drug Designation, we believe this ODD designation provides strong validation of our science and our approach to treat this disease" concludes Dr. Sinkule.
In addition, the company also announced:
“Klotho Neurosciences, Inc. Partners with AAVnerGene Inc. to Make Klotho's Gene Therapy Assets”
Here are some of the comments from this press release:
"AAV gene therapy has been proven to be a revolutionary one-time, life-changing treatment, however it is experiencing some crisis caused by high drug price and high dose-related toxicity," said Dr. Daozhan Yu, Founder and CEO of AAVnerGene. "We envisioned these bottleneck problems six years ago and AAVnerGene was founded with the mission to solve them. With the two proprietary platforms, we can dramatically drive down the manufacture cost with the AAVone system and the dose required by the highly efficient and specific tissue-targeting AAVs developed with the ATHENA platform. It's a perfect synergy to partner with Klotho, a neuroscience-driven pathfinder. Neurological disease drug development is always challenging and we need new approaches and mechanisms. Klotho's data on neuron protection and longevity are very impressive and it holds the potential to treat so many devastating diseases. We are very glad to work with the passionate and highly executive team, and strongly believe that the collaboration can bring more affordable and innovative drugs for patients with rare and common diseases."
Dr. Joseph Sinkule concluded "Klotho believes AAVnerGene has conceived a process method that is more cost effective, faster to make, has fewer impurities, shows higher efficacy and lower toxicity because of the higher targeted tissue delivery. KLTO hopes to work with AAVnerGene for manufacturing several of our product candidates composed of a tissue-specific promoter driving our Klotho gene to produce the Klotho protein and elevated concentrations of the protein in specific, targeted tissues and organs affected by these neurologic and neuromuscular diseases."
Plus, the company also announced:
“Klotho Neurosciences, Inc. to Expand Development Programs Beyond Neurology”
Here are some of the company’s comments from this press release:
"As announced previously, we've begun manufacturing and development of KLTO-101 and KLTO-202," said Klotho CEO Dr. Joseph Sinkule. "We're also exploring other treatments that could support healthy aging and extend human longevity."
Furthermore:
"The Klotho gene is what we call a master gene," stated Shalom Hirschman, M.D., world-renowned physician and senior consultant to the Company. "The Klotho gene has pleotropic actions modulating many critical cellular pathways including insulin resistance, insulin-like growth factor-1, FOXO3 transcription factors, and Wnt signaling pathways leading to the reduction of inflammatory and mitochondrial oxidative stresses and other cell-damaging mechanisms that can be prevented by two alpha-Klotho protein isoforms – soluble Klotho and secreted-Klotho."
"We're assembling a team of scientists, clinicians, and business leaders focused on identifying key longevity indicators," said Jeffrey LeBlanc, Klotho CFO. "This includes evaluating genes and proteins such as alpha-Klotho, beta-Klotho, FOXO3, anti-myostatin, and their isoforms."
Importantly:
Dr. Sinkule added, "If people don't die of cancer or trauma, they often succumb to age-related diseases of the brain, heart, kidneys, liver, bone, or muscle. Our mission is to identify and develop complementary assets to delay these outcomes through targeted research and intervention."
Last week, on Tuesday, the company announced:
“Klotho Neurosciences, Inc. (KLOTHO) Initiates Manufacturing of KLTO-202 Product Candidate Using AAVnerGene's Platform Technology”
Here are some of the company’s comments from this press release:
“Dr. Joseph Sinkule, KLOTHO CEO, stated, "The AAVnerGene technology is a game-changer in manufacturing AAV vectors for intracellular delivery of genes. The initiation of manufacturing is a key milestone in the development of any biotech product, and the manufacturing of gene therapy products presents particular complications. KLOTHO is using AAVnerGene's cutting-edge 'AAVone' platform technology and engineered HEK293 cell line to introduce the plasmid DNA containing our Klotho gene, so that the AAV particles containing our gene are at a higher-than-normal titer concentration, have fewer impurities, and can be optimized and produced faster than the old standard method. We believe that working with AAVnerGene as our development partner has the potential to launch our product candidates into the clinic at a faster pace, lower cost, higher efficacy, and higher purity compared to the current 'triple transfection' manufacturing method."”
In addition, just this morning the company announced breaking news:
“Klotho Neurosciences Provides Shareholder Update Highlighting Recent Milestones as It Prepares to Address $8 Billion Neurodegenerative Disease Market”
“Key partnerships, regulatory progress, manufacturing advancements, along with significant capital infusion accelerate the development of Klotho-based therapeutics”
KLTO could be positioned for increased growth potential.
Make sure to do your own due diligence.
Happy Trading!
SmallCapStocks Team
Note: We encourage all traders and investors to develop personal trading rules that you can follow and that work for you. Always protect your downside and note that we alert extremely volatile short-term opportunities. Before investing in securities, you should always consult with your financial, tax and legal advisor and never invest money you cannot afford to lose.
DISCLAIMER:
You should read and understand this disclaimer in its entirety before joining the website or email/blog list of SmallCapStocks.com (the “Publisher”). The information (collectively the “Advertisement”) disseminated by email, text or other method by the Publisher including this publication is a paid commercial advertisement and should not be relied upon for making an investment decision or any other purpose. The Publisher is engaged in the business of marketing and advertising the securities of publicly traded companies in exchange for compensation. The track record, gains, upside, and/or losses mentioned in the Advertisement, if any, should not be considered as true or accurate or be the basis for an investment. The Publisher does not verify the accuracy or completeness of any information included in the Advertisement. While the Publisher does not charge for the SMS service, standard carrier message and data rates may apply. To unsubscribe from receiving promotional text messages to your phone sent via an autodialer, using your phone reply to the sender’s phone number with the word STOP or HELP for help.
The Advertisement is not a solicitation or recommendation to buy securities of the advertised company. An offer to buy or sell securities can be made only by a disclosure document that complies with applicable securities laws and only in the states or other jurisdictions in which the security is eligible for sale. The Advertisement is not a disclosure document. The Advertisement is only a favorable snapshot of unverified information about the advertised company. An investor considering purchasing the securities, should always do so only with the assistance of his legal, tax and investment advisors. Investors should review with his or her investment advisor, tax advisor or attorney, if and to the extent available, any information concerning a potential investment at the web sites of the U.S. Securities and Exchange Commission (the "SEC") at www.sec.gov; the Financial Industry Regulatory Authority (the "FINRA") at www.FINRA.org, and relevant State Securities Administrator website and the OTC Markets website at www.otcmarkets.com. The Publisher cautions investors to read the SEC advisory to investors concerning Internet Stock Fraud at www.sec.gov/consumer/cyberfr.htm, as well as related information published by the FINRA on how to invest carefully. Investors are responsible for verifying all information in the Advertisement. As an advertiser, we do not verify any information we publish. The Advertisement should not be considered true or complete.
The Publisher does not offer investment advice or analysis, and the Publisher further urges you to consult your own independent tax, business, financial and investment advisors concerning any investment you make in securities particularly those quoted on the OTC Markets. Investing in securities is highly speculative and carries an extremely high degree of risk. You could lose your entire investment if you invest in any company mentioned in the Advertisement. You acknowledge that we are not an investment advisory service, a broker-dealer or an investment adviser and we are not qualified to act as such. You acknowledge that you will consult with your own independent, tax, financial and/or legal advisers regarding any decisions as to any company mentioned here. We have not determined if the Advertisement is accurate, correct or truthful. The Advertisement is compiled from publicly available information, which include, but are not limited to, no cost online research, magazines, newspapers, reports filed with the SEC or information furnished by way of press releases. Because all information relied upon by us in preparing an advertisement about an issuer comes from a public source, it is not reliable, and you should not assume it is accurate or complete.
Owners and operators of the Publisher have been compensated seven thousand five hundred dollars by bank wire transfer on 8/13/25 for the distribution of this advertisement about KLTO dated 8/18/25. The Publisher and its owners and operators hold no stocks or bonds in companies discussed in the Advertisement. Owners and operators of the Publisher own several newsletters, therefore you may receive multiple publications and emails featuring companies at different or the same time.
You are receiving this report/release because you subscribed to receive it at our website or through a third-party site. All our newsletters include an "unsubscribe" link, and you can remove yourself at any time from our newsletters by clicking on that "unsubscribe" link. You can also contact us at [email protected] to change your information at any time. By your subscription to our profiles, the viewing of this profile and/or use of our website, you have agreed and acknowledged the terms of our full disclaimer and privacy policy which can be viewed at the following link:
By accepting the Advertisement, you agree and acknowledge that any hyperlinks to the website of (1) a client company, (2) the party issuing or preparing the information for the company, or (3) other information contained in the Advertisement is provided only for your reference and convenience. The advertiser is not responsible for the accuracy or reliability of these external sites, nor is it responsible for the content, opinions, products or other materials on external sites or information sources. If you use, act upon or make decisions in reliance on information contained in any disseminated report/release or any hyperlink, you do so at your own risk and agree to hold us, our officers, directors, shareholders, affiliates and agents harmless. You acknowledge that you are not relying on the Publisher, and we are not liable for, any actions taken by you based on any information contained in any disseminated email or hyperlink.